dan 2163 has been researched along with physostigmine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Hardern, R; Page, AV; Teoh, R | 1 |
3 other study(ies) available for dan 2163 and physostigmine
| Article | Year |
|---|---|
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Physostigmine as treatment for severe CNS anticholinergic toxicity.
Topics: Amisulpride; Antipsychotic Agents; Cholinesterase Inhibitors; Drug Overdose; Humans; Male; Muscarinic Antagonists; Physostigmine; Poisoning; Procyclidine; Sulpiride | 2001 |